BSX vs PFE
BSX: A global medical-device innovator developing minimally invasive solutions for cardiovascular, rhythm management, and endoscopic procedures. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | BSX | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $44.99 | $24.25 | |
| Market cap as of 2026-07-10 | $66.9B | $138.1B | |
| P/E as of 2026-07-10 | 18.77 | 18.44 | PFE lower |
| PEG as of 2026-07-10 | 0.25 | -3.38 | PFE lower |
| Net margin as of 2026-07-10 | +17.3% | +11.8% | BSX higher |
| Gross margin as of 2026-07-10 | +69.1% | +74.8% | PFE higher |
| Operating margin as of 2026-07-10 | +18.4% | +15.4% | BSX higher |
| ROE as of 2026-07-10 | +14.9% | +8.4% | BSX higher |
| ROA as of 2026-07-10 | +8.3% | +3.6% | BSX higher |
| Debt / equity as of 2026-07-10 | 0.43 | 0.72 | BSX lower |
| Revenue growth (YoY) as of 2026-07-10 | +17.4% | +1.4% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | -14.8% | BSX higher |
| Dividend yield as of 2026-07-10 | +0.0% | +7.1% | PFE higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.58 | 0.29 | |
| 1-year return as of 2026-07-09 close | -56.2% | -5.1% | PFE higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.